Advertisement

Organisation › Details
Neovacs S.A. (Euronext Growth Paris: ALNEV)
Listed on Euronext Growth since 2010, Neovacs is today a leading biotechnology company focused on an active immunotherapy technology platform (Kinoids) with applications in autoimmune and/or inflammatory diseases. On the basis of the company’s proprietary technology for inducing a polyclonal immune response (covered by four patent families that potentially run until 2032) Neovacs is focusing its clinical development efforts on IFNa Kinoid, an immunotherapy being developed for the indication of lupus, dermatomyositis and also in preclinical trial for Type 1 diabetes. Neovacs is also conducting preclinical development works on other therapeutic vaccines in the fields of auto-immune diseases, oncology and allergies. The goal of the Kinoid approach is to enable patients to have access to safe treatments with efficacy that is sustained in these life-long diseases. *
![]() |
Start | 2010-05-21 existent |
Group | Neovacs (Group) | |
![]() |
Industry | therapeutic vaccine |
Industry 2 | TNF-Kinoid | |
![]() |
Person | Sieler, Miguel (Neovacs 201310 CEO before Bayer France CEO at Bayer since 1975) |
Person 2 | Fanneau de la Horie, Guy-Charles (Pherecydes Pharma 201602– CEO before PathoQuest + Neovacs + Biogen) | |
![]() |
Region | Paris |
Country | France | |
Street | 3–5 Impasse Reille | |
City | 75014 Paris | |
Tel | +33-1-5310-9300 | |
Address record changed: 2024-01-05 | ||
Basic data | Employees | B: 11 to 50 (2014-11-01) |
Currency | EUR | |
Annual sales | 394,000 (revenues (2016) 2016-12-31) | |
Profit | -13,932,000 (2016-12-31) | |
Cash | 3,900,000 (2016-12-31) | |
* Document for »About Section«: | ||
Record changed: 2024-02-12 |
Advertisement

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to [email protected] and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement

» top